Jazz Pharmaceuticals announced on Thursday that its experimental drug, Suvecaltamide (JZP385), aimed at treating essential tremor, failed to meet the primary endpoint in a Phase 2b trial. The drug, which targets a neurological condition characterized by involuntary and rhythmic shaking, did not reduce tremor severity in the mid-stage study. Following the announcement, Jazz Pharmaceuticals' shares dropped by 5% in morning trading, with a pre-market decline of 2.4%.
News Roundup: Jazz drug for tremor fails study; Radiopharma drug developer ITM swaps CEOs https://t.co/YmKqId055H
Jazz Pharmaceuticals said on Thursday its experimental drug to treat a common movement disorder failed to reduce tremor severity in a mid-stage study, sending the company's shares down 5% in morning trading. https://t.co/E5RSA36ya3 https://t.co/E5RSA36ya3
Jazz Pharmaceuticals' tremor drug fails to meet main goal in mid-stage study https://t.co/J3UUq1p0gr https://t.co/OnLULb0DVF
$JAZZ (-2.4% pre) Jazz Pharma slips as mid-stage trial for neuro candidate fails - SA https://t.co/GlgFEtTT4n
Jazz Pharmaceuticals said on Thursday its experimental drug to treat a neurological condition that causes involuntary and rhythmic shaking failed to meet the main goal in a mid-stage study. https://t.co/k2bvdFSHuo https://t.co/k2bvdFSHuo
Jazz Pharmaceuticals Provides Update on Phase 2b Trial of Investigational Suvecaltamide (JZP385) in Essential Tremor $JAZZ https://t.co/7TJ5bFaljc